TWI834791B - 吡咯啶化合物的結晶 - Google Patents

吡咯啶化合物的結晶 Download PDF

Info

Publication number
TWI834791B
TWI834791B TW108148109A TW108148109A TWI834791B TW I834791 B TWI834791 B TW I834791B TW 108148109 A TW108148109 A TW 108148109A TW 108148109 A TW108148109 A TW 108148109A TW I834791 B TWI834791 B TW I834791B
Authority
TW
Taiwan
Prior art keywords
crystal
crystals
phosphoric acid
patent application
compound
Prior art date
Application number
TW108148109A
Other languages
English (en)
Chinese (zh)
Other versions
TW202039464A (zh
Inventor
上田直子
長田裕臣
紘
Original Assignee
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商田邊三菱製藥股份有限公司 filed Critical 日商田邊三菱製藥股份有限公司
Publication of TW202039464A publication Critical patent/TW202039464A/zh
Application granted granted Critical
Publication of TWI834791B publication Critical patent/TWI834791B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108148109A 2018-12-28 2019-12-27 吡咯啶化合物的結晶 TWI834791B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-247437 2018-12-28
JP2018247437 2018-12-28

Publications (2)

Publication Number Publication Date
TW202039464A TW202039464A (zh) 2020-11-01
TWI834791B true TWI834791B (zh) 2024-03-11

Family

ID=71127176

Family Applications (3)

Application Number Title Priority Date Filing Date
TW108148109A TWI834791B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶
TW113104509A TWI870228B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶
TW113147267A TWI919623B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW113104509A TWI870228B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶
TW113147267A TWI919623B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶

Country Status (8)

Country Link
US (2) US12077524B2 (enExample)
EP (4) EP3903785B1 (enExample)
JP (3) JP6977185B2 (enExample)
CN (3) CN120081826A (enExample)
ES (1) ES2991904T3 (enExample)
MA (1) MA54619A (enExample)
TW (3) TWI834791B (enExample)
WO (1) WO2020138481A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122595A1 (es) 2020-06-10 2022-09-21 Mitsubishi Tanabe Pharma Corp Agente profiláctico o terapéutico para fotodermatosis
KR102952931B1 (ko) 2020-06-10 2026-04-15 다나베 파마 가부시키가이샤 포르피린증의 예방 또는 치료제
CN122557552A (zh) * 2020-06-10 2026-08-14 田边制药株式会社 卟啉症的预防或治疗剂
CN117255786A (zh) * 2021-05-06 2023-12-19 株式会社Lg 化学 黑皮质素受体激动剂化合物的晶型vii及其制备方法
KR102854595B1 (ko) * 2021-05-06 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법
KR102854598B1 (ko) * 2021-05-07 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법
JP2024517271A (ja) * 2021-05-07 2024-04-19 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
KR20240145490A (ko) 2022-01-31 2024-10-07 미쓰비시 타나베 파마 코퍼레이션 멜라노코르틴 1 수용체 아고니스트의 신규 용도
WO2024029599A1 (ja) 2022-08-03 2024-02-08 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182723A1 (ja) * 2014-05-29 2015-12-03 田辺三菱製薬株式会社 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182723A1 (ja) * 2014-05-29 2015-12-03 田辺三菱製薬株式会社 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
ES2991904T3 (es) 2024-12-05
TWI919623B (zh) 2026-03-21
MA54619A (fr) 2021-11-03
CN120081827A (zh) 2025-06-03
JP2025085744A (ja) 2025-06-05
WO2020138481A1 (ja) 2020-07-02
JP7652682B2 (ja) 2025-03-27
EP3903785A4 (en) 2022-08-10
EP4603143A3 (en) 2025-11-05
EP4603143A2 (en) 2025-08-20
EP3903785A1 (en) 2021-11-03
TWI870228B (zh) 2025-01-11
TW202039464A (zh) 2020-11-01
CN113226314A (zh) 2021-08-06
TW202421621A (zh) 2024-06-01
JPWO2020138481A1 (ja) 2021-09-27
CN120081826A (zh) 2025-06-03
EP3903785B1 (en) 2024-10-02
EP4434582A3 (en) 2024-12-18
US12077524B2 (en) 2024-09-03
TW202517631A (zh) 2025-05-01
JP2022024034A (ja) 2022-02-08
EP4434582A2 (en) 2024-09-25
JP6977185B2 (ja) 2021-12-08
US20250002474A1 (en) 2025-01-02
CN113226314B (zh) 2025-03-18
EP4763282A2 (en) 2026-06-24
US20220073497A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
TWI919623B (zh) 吡咯啶化合物的結晶
CN114728899B (zh) 新型三苯基化合物盐
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP7153030B6 (ja) オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
TW200845998A (en) Heterocyclic compounds useful in treating diseases and conditions
CN105899215A (zh) 十六烷氧基丙基膦酸酯的形态
HK40130190A (en) Crystal of pyrrolidine compound
WO2026103747A1 (zh) 一种噻唑类衍生物抑制剂的盐、其晶型及其制备方法和应用
ES2386029T3 (es) Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo
HK40076742B (en) Novel salt of terphenyl compound
CA2657117A1 (en) Crystals of benzoxadiazole derivative
US20140275105A1 (en) Crystal of androgen receptor antagonistic compound